Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen: the Italian HENIVOT study in Jama
Use of the helmet reduces the need for intubation by Covid: “This study confirms that SIAARTI is at the forefront in identifying new and better therapeutic paths”, stresses President Flavia Petrini
An Italian multicentre trial fully financed by the Italian Society of Anaesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) has just been published in the prestigious Journal of the American Medical Association-JAMA: the HENIVOT study, a trial coordinated by Policlinico Universitario Agostino Gemelli Irccs with the participation of Ospedale degli Infermi di Rimini and the Universities of Ferrara, Chieti and Bologna.
The PDF of the HENIVOT (Helmet Noninvasive Ventilation) study is at the end of this article.
HENIVOT study: helmet use in covid patients compared with oxygen therapy
The study, whose first signatory was Domenico Luca Grieco (Resuscitator, Intensive Care, Columbus Covid2 Hospital, Fondazione Policlinico Universitario Agostino Gemelli Irccs) and the participation – among others – of Professor Massimo Antonelli (Director of Anaesthesia, Resuscitation, Intensive Care and Clinical Toxicology, Fondazione Policlinico Universitario Agostino Gemelli Irccs, Professor of Anaesthesiology and Reanimation at the Catholic University), involved 109 patients and demonstrated that the use of a specific and innovative helmet produced in Italy allows patients with severe respiratory insufficiency (such as those with Covid-19 pneumonia) to breathe, reducing the need for intubation by 40%.
The data – decidedly interesting and promising – are compared with high-flow oxygen therapy, which is currently considered the optimal respiratory support in cases of hypoxemia.
This study, supported by SIAARTI, confirms that the national scientific society of anaesthesiologists and resuscitators is at the forefront in identifying new and better therapeutic paths, and in the appropriate indication of devices,” emphasises Flavia Petrini, president of SIAARTI.
The opportunity to have at our disposal the latest generation of healthcare technologies designed and developed in our country, but above all the ability of Italian researchers to identify how they should be managed and monitored: all this offers intensive care specialists important therapeutic weapons and confirms our professional vocation to be protagonists in the development of new care pathways and best practices for critical patients.
Our hope, therefore, is that what is being tested today with such promising results in a still limited patient population, if supported by even more robust evidence, may in the near future become a new standard of care for the whole world of intensive care”.